Viatris, which was officially launched at the end of last year, had low sales in the first half of this year. The amount of outpatient prescriptions for major products decreased by 8% compared to the first half of last year before independence from the Pfizer.

Organon, separated from MSD, has a similar situation. Prescription performance of major products decreased by 8% during the same period. Foreign prescription sales were low due to prolonged COVID-19 outbreak.

◆The first half of Lipitor prescription was reduced by 8%

According to UBIST, a pharmaceutical market research institute on the 28th, Viatris' total amount of prescriptions for major out-of-the-r